Do inhaled anticholinergics increase or decrease the risk of major cardiovascular events? A synthesis of the available evidence

Drugs

Volumn 69, Issue 15, 2009, Pages 2025-2033

  Salpeter, Shelley R ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SANTA CLARA VALLEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; IPRATROPIUM BROMIDE; SCOPOLAMINE DERIVATIVE; TIOTROPIUM BROMIDE;

ARTICLE; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; CHRONIC OBSTRUCTIVE LUNG DISEASE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MORTALITY; RISK;

ADMINISTRATION, INHALATION; BRONCHODILATOR AGENTS; CARDIOVASCULAR DISEASES; CHOLINERGIC ANTAGONISTS; HUMANS; IPRATROPIUM; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK; SCOPOLAMINE DERIVATIVES;

EID: 72149128736     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11318580-000000000-00000     Document Type: Review

References (53)

1. Global Initiative for Chronic Obstructive Lung Disease. Guidelines: global strategy for diagnosis, management, and prevention of COPD [online]. Available from URL: http://www.goldcopd.org/Guidelineitem.asp?l1=2&l2= 1&intId=2003 [Accessed 2009 May 21]
2. Petty TL. Definition, epidemiology, course, and prognosis of COPD. Clin Cornerstone 2003; 5 (1): 1-10
3. Holguin F, Folch E, Redd SC, et al. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest 2005 Oct; 128 (4): 2005-11
4. Sin DD, Man SF. Chronic obstructive pulmonary disease: a novel risk factor for cardiovascular disease. Can J Physiol Pharmacol 2005 Jan; 83 (1): 8-13
5. Halpin D. Mortality in COPD: inevitable or preventable? Insights from the cardiovascular arena. COPD 2008 Jun; 5 (3): 187-200
6. 2-adrenoceptor agonist use in patients with obstructive airway disease: a systematic review. Drugs Aging 2004; 21 (6): 405-14
7. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest 2004 Jun; 125 (6): 2309-21
8. Au DH, Lemaitre RN, Curtis JR, et al. The risk of myocardial infarction associated with inhaled beta-adrenoceptor agonists. Am J Respir Crit Care Med 2000 Mar; 161 (3 Pt 1): 827-30
9. Coughlin SS, Metayer C, McCarthy EP, et al. Respiratory illness, beta-agonists, and risk of idiopathic dilated cardio-myopathy: the Washington, DC, Dilated Cardiomyopathy Study. Am J Epidemiol 1995 Aug 15; 142 (4): 395-403
10. Sengstock DM, Obeidat O, Pasnoori V, et al. Asthma, betaagonists, and development of congestive heart failure: results of the ABCHF study. J Card Fail 2002 Aug; 8 (4): 232-8
11. Macie C, Wooldrage K, Manfreda J, et al. Cardiovascular morbidity and the use of inhaled bronchodilators. Int J Chron Obstruct Pulmon Dis 2008; 3 (1): 163-9
12. Sin DD, Man SF. Impact of cancers and cardiovascular diseases in chronic obstructive pulmonary disease. Curr Opin Pulm Med 2008 Mar; 14 (2): 115-21
13. Lusuardi M, Garuti G, Massobrio M, et al. Heart and lungs in COPD: close friends in real life - separate in daily medical practice? Monaldi Arch Chest Dis 2008 Mar; 69 (1): 11-7
14. Lee TA, Pickard AS, Au DH, et al. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med 2008 Sep 16; 149 (6): 380-90
15. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008 Sep 24; 300 (12): 1439-50
16. Ogale SS, Lee TA, Au DH, et al. Cardiovascular events associated with ipratropium bromide in COPD. Chest. Epub 2009 Apr 10
17. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008 Oct 9; 359 (15): 1543-54
18. Anthonisen NR, Connett JE, Enright PL, et al. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002 Aug 1; 166 (3): 333-9
19. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007 Feb 22; 356 (8): 775-89
20. Barnes PJ. The role of anticholinergics in chronic obstructive pulmonary disease. Am J Med 2004 Dec 20; 117 Suppl. 12A: 24-32S
21. Salpeter SR, Buckley NS, Salpeter EE. Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD. J Gen Intern Med 2006 Oct; 21 (10): 1011-9
22. Barr RG, Bourbeau J, Camargo CA, et al. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax 2006 Oct; 61 (10): 854-62
23. Barr RG, Bourbeau J, Camargo CA, et al. Inhaled tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005; (2): CD002876
24. Salpeter SR, Buckley NS. Systematic review of clinical outcomes in chronic obstructive pulmonary disease: beta-agonist use compared with anticholinergics and inhaled corticosteroids. Clin Rev Allergy Immunol 2006; 31 (2-3): 219-30
25. Gershon AS, Wang L, To T, et al. Survival with tiotropium compared to long-acting beta-2-agonists in chronic obstructive pulmonary disease. COPD 2008 Aug; 5 (4): 229-34
26. Oba Y, Zaza T, Thameem DM. Safety, tolerability and risk benefit analysis of tiotropium in COPD. Int J Chron Obstruct Pulmon Dis 2008; 3 (4): 575-84
27. Kesten S, Jara M, Wentworth C, et al. Pooled clinical trial analysis of tiotropium safety. Chest 2006 Dec; 130 (6): 1695-703
28. Caillaud D, Le Merre C, Martinat Y, et al. A dose-ranging study of tiotropium delivered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. Int J Chron Obstruct Pulmon Dis 2007; 2 (4): 559-65
29. Blomstrom-Lundqvist C, Scheinman MM, Aliot EM, et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supra-ventricular Arrhythmias). Circulation 2003 Oct 14; 108 (15): 1871-909
30. Julius S, Palatini P, Nesbitt SD. Tachycardia: an important determinant of coronary risk in hypertension. J Hypertens Suppl 1998 Jan; 16 (1): S9-15
31. Umana E, Solares CA, Alpert MA. Tachycardia-induced cardiomyopathy. Am J Med 2003 Jan; 114 (1): 51-5
32. Berton GS, Cordiano R, Palmieri R, et al. Heart rate during myocardial infarction: relationship with one-year global mortality in men and women. Can J Cardiol 2002 May; 18 (5): 495-502
33. Jouven X, Zureik M, Desnos M, et al. Resting heart rate as a predictive risk factor for sudden death in middle-aged men. Cardiovasc Res 2001 May; 50 (2): 373-8
34. Rodrigo GJ, Castro-Rodriguez JA, Nannini LJ, et al. Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: systematic review with meta-analysis. Respir Med. Epub 2009 Jun 23
35. Sindi A, McIvor A. The use of inhaled anticholinergics in chronic obstructive pulmonary disease: is there cause for concern? A review of evidence from clinical trials. Pol Arch Med Wewn 2009 Jan-Feb; 119 (1-2): 74-8
36. Celli B, Decramer M, Leimer I, et al. Cardiovascular safety of tiotropium in patients with COPD. Chest. Epub 2009 Jul 10
37. Lanes S, Golisch W, Mikl J. Ipratropium and lung health study. AmJ Respir Crit Care Med 2003 Mar 1; 167 (5): 801; author reply 802
38. Kesten S, Plautz M, Piquette CA, et al. Premature discontinuation of patients: a potential bias in COPD clinical trials. Eur Respir J 2007 Nov; 30 (5): 898-906
39. Chest 2008: a review of anticholinergic inhalers for COPD patients. Developed by session faculty and the ACCP COPD Task Force [online]. Available from URL: http://www.chestnet.org/networks/airway-disorders/ ACCPAnticholinergics.pdf [Accessed 2009 Aug 24]
40. Singh S, Furberg CD, Loke YK. Tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2009 Jan 8; 360 (2): 186; author reply 187
41. Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD [published erratum appears in Thorax 2005; 60 (2): 105].
42. Thorax 2003; 58 (5): 399-404
43. Casaburi R, Briggs Jr DD, Donohue JF, et al., US Tiotropium Study Group. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. Chest 2000; 118 (5): 1294-302
44. Casaburi R, Mahler DA, Jones PW, et al. A longterm evaluation of once daily-inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19 (2): 217-24
45. Chan CK, Maltais F, Sigouin C, et al., SAFE Study Group. A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease. Can Respir J 2007; 14 (8): 465-72
46. Covelli H, Bhattacharya S, Cassino C, et al. Absence of electrocardiographic findings and improved function with once-daily tiotropium in patients with chronic obstructive pulmonary disease. Pharmacotherapy 2005; 25 (12): 1708-18
47. GlaxoSmithKline. Clinical trial register for a multicenter, randomized, double-blind, double-dummy, parallel group, 8-week comparison of salmeterol xinafoate versus ipratropium bromide versus salmeterol xinafoate plus ipratropium bromide versus placebo in subjects with chronic obstructive pulmonary disease [online]. Available from URL: http://ctr.gsk.co.uk/Summary/ salmeterol/IV-SMS40315.pdf [Accessed 2008 Aug 5]
48. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115 (4): 957-65
49. Moita J, Barbara C, Cardoso J, et al. Tiotropium improves FEV1 in patients with COPD irrespective of smoking status. Pulm Pharmacol Ther 2008; 21 (1): 146-51
50. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic broncho-dilator: a randomized trial. Ann Intern Med 2005; 143 (5): 317-26
51. Powrie DJ, Wilkinson TMA, Donaldson GC, et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur Respir J 2007; 30 (3): 472-8
52. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-54
53. Voshaar T, Lapidus R, Maleki-Yazdi R, et al. A randomized study of tiotropium respimat soft Mist™ inhaler vs. ipratropium pMDI in COPD. Respir Med 2008; 102 (1): 32-41